Hirudinaria manillensis Multimeric Decorsins
One monomeric + four multimeric decorsin paralogs from Asian buffalo leech — Tolksdorf 2025 demonstrates platelet-aggregation inhibitory activity for all but one paralog.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- One monomeric + four multimeric decorsin paralogs from Asian buffalo leech — Tolksdorf 2025 demonstrates platelet-aggregation inhibitory activity for all but one paralog.
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
Multimeric decorsins' in vitro platelet inhibition does NOT establish clinical efficacy. No FDA-approved multimeric decorsin derivative exists; clinical RGD-mimetic GPIIb/IIIa antagonists (eptifibatide, tirofiban) are monovalent synthetic peptidomimetics, not multimeric.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Molecular weight
- 16,000 Da
- Source species
- Hirudinaria manillensis
- Discovered
- 2025 · Tolksdorf C et al.
Biological Targets
- → platelet integrin αIIbβ3 (multivalent RGD binding via multiple decorsin domains)
Key Citations
- Tolksdorf C et al. (2025), Int J Mol Sci · PMID 41303498
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.